These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33448893)

  • 21. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
    Plosker GL; Carter NJ
    Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan.
    Ishizawa K; Yokoyama M; Kato H; Yamamoto K; Makita M; Ando K; Ueda Y; Tachikawa Y; Suehiro Y; Kurosawa M; Kameoka Y; Nagai H; Uoshima N; Ishikawa T; Hidaka M; Ito Y; Utsunomiya A; Fukushima K; Ogura M
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):83-95. PubMed ID: 35796785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
    Baek GT; Mathis NJ; Perissinotti AJ; Marini BL; Brown A; Phillips TJ; Wilcox RA; Nachar VR
    Leuk Lymphoma; 2021 Dec; 62(13):3138-3146. PubMed ID: 34263702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.
    Vannata B; Vanazzi A; Negri M; Liptrott SJ; Bartosek AA; Miani M; Di Sanzo A; Cavalli F; Zucca E; Stathis A
    Hematol Oncol; 2021 Feb; 39(1):60-65. PubMed ID: 33103778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
    Rummel MJ; Mitrou PS; Hoelzer D
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
    Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
    de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
    Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
    Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA
    Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
    J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
    Brugger W; Ghielmini M
    Oncologist; 2013; 18(8):954-64. PubMed ID: 23900001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
    Uchida M; Mori Y; Akiba K; Miyasaka M; Hirano T; Ikesue H; Yamaguchi Y; Takano A; Maegawa N; Shimomura Y; Hosohata K; Muroi N; Ishikawa T; Hashida T; Nakamura T
    Biol Pharm Bull; 2020 Oct; 43(10):1577-1582. PubMed ID: 32801282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
    Kotchetkov R; Drennan IR; Susman D; DiMaria E; Gerard L; Nay D; Prica A
    Int J Cancer; 2023 May; 152(9):1884-1893. PubMed ID: 36545885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
    Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
    Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
    Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD
    Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Darwish M; Burke JM; Hellriegel E; Robertson P; Phillips L; Ludwig E; Munteanu MC; Bond M
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1119-27. PubMed ID: 24677018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Cencini E; Sicuranza A; Fabbri A; Ferrigno I; Rigacci L; Cox MC; Raspadori D; Bocchia M
    Br J Haematol; 2019 Jan; 184(2):223-231. PubMed ID: 30203425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.